Pericardial Diseases in Pregnancy.
Journal
The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
15
12
2022
revised:
13
04
2023
accepted:
14
04
2023
medline:
14
8
2023
pubmed:
23
4
2023
entrez:
22
04
2023
Statut:
ppublish
Résumé
Pericardial effusion is the most common manifestation of pericardial diseases during pregnancy. This effusion is benign, mild, or moderate, well tolerated, with spontaneous resolution after delivery; no specific treatment is required. Acute pericarditis is the second most common condition, usually requiring medical therapy during pregnancy. Cardiac tamponade and constrictive pericarditis are rare in pregnancy. Pre-pregnancy counselling is essential in women of childbearing age with recurrent pericarditis to plan pregnancy in a phase of disease quiescence and to review therapy. High-dose aspirin or nonselective nonsteroidal anti-inflammatory drugs, such as ibuprofen and indomethacin, can be used up to the 20th week of gestation. Low-dose prednisone (2.5-10 mg/d) can be administered throughout pregnancy. All of these medications, apart from high-dose aspirin, may be used during lactation. Colchicine is compatible with pregnancy and breastfeeding, and it can be continued throughout pregnancy to prevent recurrences. Appropriate follow-up with a multidisciplinary team with experience in the field is recommended throughout pregnancy to ensure good maternal and fetal outcomes.
Identifiants
pubmed: 37086835
pii: S0828-282X(23)00311-2
doi: 10.1016/j.cjca.2023.04.010
pii:
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067-1077Informations de copyright
Copyright © 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.